Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN – Research Report), Teleflex (TFX – Research Report) and Axsome Therapeutics (AXSM – Research Report).
Amgen (AMGN)
In a report issued on May 6, Salim Syed from Mizuho Securities assigned a Hold rating to Amgen, with a price target of $223.00. The company’s shares closed last Tuesday at $300.30.
According to TipRanks.com, Syed has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amgen with a $321.29 average price target, which is a 6.5% upside from current levels. In a report issued on May 3, Barclays also upgraded the stock to Hold with a $300.00 price target.
See the top stocks recommended by analysts >>
Teleflex (TFX)
Mizuho Securities analyst Anthony Petrone maintained a Hold rating on Teleflex on May 3 and set a price target of $275.00. The company’s shares closed last Tuesday at $201.52.
According to TipRanks.com, Petrone is a 4-star analyst with an average return of
Teleflex has an analyst consensus of Moderate Buy, with a price target consensus of $248.80, which is a 23.3% upside from current levels. In a report issued on May 2, Needham also maintained a Hold rating on the stock.
Axsome Therapeutics (AXSM)
Mizuho Securities analyst Graig Suvannavejh assigned a Buy rating to Axsome Therapeutics on May 6 and set a price target of $109.00. The company’s shares closed last Tuesday at $76.94.
According to TipRanks.com, Suvannavejh is ranked 0 out of 5 stars with an average return of
Axsome Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $119.58, representing a 58.2% upside. In a report issued on April 29, Morgan Stanley also upgraded the stock to Buy with a $115.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AMGN:
- Fly Insider: Theravance Bio, Amgen among week’s notable insider trades
- CytomX Therapeutics upgraded to Buy from Hold at Jefferies
- Amgen price target raised to $325 from $315 at BofA
- Amgen price target lowered to $328 from $332 at RBC Capital
- Early notable gainers among liquid option names on May 3rd
